The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma
Please always quote using this URN: urn:nbn:de:bvb:20-opus-231862
- Lenalidomide is an integral, yet evolving, part of current treatment pathways for both transplant-eligible and transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). It is approved in combination with dexamethasone as first-line therapy for transplant-ineligible patients with NDMM, and as maintenance treatment following autologous stem cell transplantation (ASCT). Although strong clinical trial evidence has supported the integration of lenalidomide into current treatment paradigms for NDMM, applying those paradigms toLenalidomide is an integral, yet evolving, part of current treatment pathways for both transplant-eligible and transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). It is approved in combination with dexamethasone as first-line therapy for transplant-ineligible patients with NDMM, and as maintenance treatment following autologous stem cell transplantation (ASCT). Although strong clinical trial evidence has supported the integration of lenalidomide into current treatment paradigms for NDMM, applying those paradigms to individual patients and determining which patients are most likely to benefit from lenalidomide treatment are more complex. In this paper, we utilize the available clinical trial evidence to provide recommendations for patient selection and lenalidomide dosing in both the first-line setting in patients ineligible for ASCT and the maintenance setting in patients who have undergone ASCT. In addition, we provide guidance on management of those adverse events that are most commonly associated with lenalidomide treatment, and consider the optimal selection and sequencing of next-line agents following long-term frontline or maintenance treatment with lenalidomide.…
Author: | Maximilian Merz, Tobias Dechow, Mithun Scheyt, Christian Schmidt, Stefan Knop |
---|---|
URN: | urn:nbn:de:bvb:20-opus-231862 |
Document Type: | Journal article |
Faculties: | Medizinische Fakultät / Medizinische Klinik und Poliklinik II |
Language: | English |
Parent Title (English): | Annals of Hematology |
ISSN: | 0939-5555 |
Year of Completion: | 2020 |
Volume: | 99 |
Pagenumber: | 1709–1725 |
Source: | Annals of Hematology 99, 1709–1725 (2020). https://doi.org/10.1007/s00277-020-04023-4 |
DOI: | https://doi.org/10.1007/s00277-020-04023-4 |
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Tag: | adverse events; lenalidomide; multiple myeloma; newly diagnosed; safety |
Release Date: | 2021/06/30 |
Licence (German): | CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International |